Drug intelligence / Profile preview

bifidobacterium adolescentis CCFM1062

Development stage: Preclinical
Lead developer: Jiangnan University
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

*Bifidobacterium adolescentis* CCFM1062 is a specific probiotic bacterial strain belonging to the species *B. adolescentis*, originally isolated and characterized by Jiangnan University and developed in collaboration with Shanghai Helplifes Technology. It is classified as a live biotherapeutic product (LBP) or functional food ingredient. Research, including studies published in peer-reviewed journals and patent CN110368406B, suggests the strain possesses psychotropic properties (psychobiotic), with potential applications in alleviating anxiety-like behaviors and modulating the gut-brain axis. It acts by colonizing the gastrointestinal tract, regulating the gut microbiota composition, and influencing neurotransmitter levels or inflammatory pathways. The strain is also investigated for its ability to improve gastrointestinal health, including the alleviation of constipation.

Other names: 青春双歧杆菌CCFM1062

Beyond the preview

Go deeper on bifidobacterium adolescentis CCFM1062.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bifidobacterium adolescentis CCFM1062.

Explore the full profile